dailynewsnblog
There is growing demand for treatments that can safely prevent and reverse bone loss over time. Osteoporosis, a condition that weakens bones and makes them more likely to break, affects about six million people in Germany alone, most of them women. It is especially common with aging and after menopause, when bone density naturally declines.
Because current treatments can have limitations or side effects, researchers are searching for new ways to strengthen bones more effectively. One promising approach involves identifying new biological targets in the body that can be used to develop better medications.
A recent study from Leipzig University highlights one such target: a receptor called GPR133. This receptor belongs to a larger family known as adhesion G protein-coupled receptors, or GPCRs. These receptors sit on the surface of cells and help transmit signals that control many processes in the body. While GPCRs are already important in medicine, this specific subgroup has not been widely studied.
The new research shows that GPR133 plays a key role in building and maintaining healthy bone.
A Receptor Linked to Bone Strength
To understand how important GPR133 is, researchers looked at what happens when it does not function properly. In animal studies, mice with genetic changes that disrupt this receptor developed low bone density early in life, closely resembling osteoporosis in humans.
“If this receptor is impaired by genetic changes, mice show signs of loss of bone density at an early age — similar to osteoporosis in humans. Using the substance AP503, which was only recently identified via a computer-assisted screen as a stimulator of GPR133, we were able to significantly increase bone strength in both healthy and osteoporotic mice,” explains Professor Ines Liebscher, lead investigator of the study from the Rudolf Schönheimer Institute of Biochemistry at the Faculty of Medicine.
The compound AP503 was discovered using computer-based screening methods that help scientists quickly identify molecules that can activate specific receptors. In this case, AP503 acts as a stimulator of GPR133.
How Bones Build and Break Down
Bone may seem like a static structure, but it is constantly being renewed. Two main types of cells control this process. Osteoblasts are responsible for building new bone, while osteoclasts break down old bone. Healthy bones depend on a careful balance between these two activities.
The researchers found that GPR133 helps regulate this balance. In bone tissue, the receptor is activated by interactions between nearby bone cells as well as by physical forces such as movement and pressure. Once activated, it sends signals that increase the activity of osteoblasts and reduce the activity of osteoclasts.
The result is stronger, denser bone that is more resistant to damage.
AP503 appears to copy this natural activation process. By turning on the same signaling pathway, it can promote bone formation and limit bone breakdown. This makes it a promising candidate for future treatments. It could potentially be used not only to protect healthy bones but also to rebuild bone in people with osteoporosis, including women after menopause.
Potential Benefits for Aging Populations
The impact of this discovery could extend beyond bone health alone. In earlier research, the same Leipzig team found that activating GPR133 with AP503 also improves skeletal muscle strength.
“The newly demonstrated parallel strengthening of bone once again highlights the great potential this receptor holds for medical applications in an aging population,” says Dr. Juliane Lehmann, lead author of the study and a researcher at the Rudolf Schönheimer Institute of Biochemistry.
Maintaining both muscle and bone strength is critical for older adults, as it reduces the risk of falls, fractures, and loss of independence. Treatments that can support both systems at once could offer significant advantages.
The research team is now continuing to study AP503 and GPR133 in greater detail. Ongoing projects aim to explore how this pathway might be used to treat other conditions and to better understand how the receptor functions throughout the body.
A Decade of Research Behind the Discovery
This breakthrough builds on more than ten years of work at Leipzig University focused on adhesion GPCRs. The research is part of Collaborative Research Centre 1423, Structural Dynamics of GPCR Activation and Signaling.
Leipzig has become an internationally recognized leader in this area, contributing important insights into how these receptors function and how they can be targeted for new therapies.
Why This Discovery Matters
Osteoporosis is often called a silent disease because bone loss can occur without noticeable symptoms until a fracture happens. By the time it is detected, significant damage may already be done.
The identification of GPR133 as a key regulator of bone strength opens up a new direction for treatment. Instead of only slowing bone loss, future therapies could actively rebuild bone and restore strength.
While more research is needed before AP503 or similar compounds are tested in humans, the findings offer a promising glimpse into a future where maintaining strong, healthy bones throughout life may become far more achievable.
